What is ORKA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.44B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ORKA?

P/E (TTM) is n/a and 52-week range is $21.66 to $115.52 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ORKA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ORKA?

The company profile lists revenue (TTM) near $47M, net income (TTM) near $-1.23B, EPS (TTM) near $-2.46 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Oruka Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Menlo Park, California, US, 60.3M shares outstanding, ISIN US6876041087 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Oruka Therapeutics Inc

$ORKA

Health Care · Biotechnology

IR Run Scenarios

$82.11

+6.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 68 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Employees

Website

orukatx.com/

IPO

2000-07-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)